Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the ... weiter zur Meldung von Sequana Medical AG
Zurich (ots) - NUB grants approval for fifteen leading hepatology centres in Germany. Sequana Medical announced today that its ALFApump® System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating ... weiter zur Meldung von Sequana Medical AG
Zurich, Switzerland (ots) - NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System ... weiter zur Meldung von Sequana Medical AG
Zurich (ots) - Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis. Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) ... weiter zur Meldung von Sequana Medical AG
Zurich, Switzerland (ots) - New technology expands treatment options for patient with refractory ascites due to liver cirrhosis. Dr. Farzana Malik joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it ... weiter zur Meldung von Sequana Medical AG
RSS
